Abstract PO5-04-14: Quality of Life (QoL) among metastatic hormone receptor positive, HER2 negative breast cancer patients during first line systemic treatment
Authors: Débora Gagliato, Julio Antonio Araujo, Bianca Milena Verboski, Guilherme William Marcelino, Fabiana Nogueira Momberg, Gilmara Silveira da Silva, Rozana Mesquita Ciconelli, Antônio Buzaid
Journal: Cancer Research (2024)

Abstract Background Current international guidelines recommend endocrine therapy combined with a CDK4/6 inhibitor as the preferred first line systemic treatment in patients diagnosed with metastatic hormone receptor positive (HR), HER2 negative breast cancer (BC). Randomized controlled trials that led to the approval of these agents in the first line disease setting are derived from controlled environments and selected patients. We aimed to assess real-world patients’ characteristics, safety and health related quality of life in a non-select cohort of patients being managed in a Brazilian private Cancer Center. Methods: We performed a cross sectional study at Beneficencia Portuguesa de Sao Paulo evaluating quality of life among patients with metastatic HR+/HER2 negative treated in the first line disease setting. Inclusion criteria included patients that received the combination of a CDK4/6i with any endocrine therapy (ET) between January 2018 and April 2023. Primary endpoint was quality of life assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC QLQ-BR23, it is baseline, there is only one measurement for each patient. Results: We analyzed 72 patients who meet the inclusion criteria. Median age at diagnosis was 49 years old (ranging from 31 to 91). Approximately half of the population was premenopausal (51%). Palbociclib and abemaciclib were the most commonly used CDK4/6i, with 42 and 35% of patients, respectively. ECOG performance status was zero or one in almost the entire patient population analyzed (97%). 53% of the patients were diagnosed as de novo metastatic BC. Table 1 and 2 summarize the patients characteristics. Mean global health status was 75.4, with social and cognitive functioning scoring the highest (Mean 78.6 and 79.1, respectively). The most distressing symptom among the symptom scale was fatigue (Mean 27.2). Most symptoms and functioning scales did not meet the threshold for clinically meaningful differences between the different CDK4/6 inhibitors. Conclusion: Real-world data from our study is consistent with the historical expected health related quality of life among patients diagnosed with HR+/HER2 negative metastatic BC in the first line disease setting. Table. Citation Format: Débora Gagliato, Julio Antonio Araujo, Bianca Milena Verboski, Guilherme William Marcelino, Fabiana Nogueira Momberg, Gilmara Silveira da Silva, Rozana Mesquita Ciconelli, Antônio Buzaid. Quality of Life (QoL) among metastatic hormone receptor positive, HER2 negative breast cancer patients during first line systemic treatment [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-04-14.